Skip to content

Study Assessing the Effects on Endometrium and Breast of Isoflavone in Post Menopausal Women

Study Assessing the Effects on Endometrium and Breast of a Standardized Isoflavone Extract(Phytosoya) in Post Menopausal Women.

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00235924
Enrollment
300
Registered
2005-10-12
Start date
2004-06-30
Completion date
Unknown
Last updated
2005-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopause

Keywords

menopause, isoflavone, endometrial safety, breast innocuity assessment, hot flushes

Brief summary

The main objective of this study is to determine the effects on the endometrium and breast of 70 mg daily dose of isoflavones.

Detailed description

This is an international multicentre open study, assessing the innocuity on breast and endometrium of a 70 mg daily dose of isoflavones standardized extract (Phytosoya). This study follows the European guidelines :one-year treatment duration, biopsy and mammography performed at the beginning and at the end of the trial, recruitment of enough subjects in order to have 300 patients with an evaluable biopsy after one year of treatment. After 3 weeks of screening phase, the patients will be taken Phytosoya during 52 weeks. At the end of the first year of treatment, an endometrial biopsy, an endovaginal ultrasonography, a mammography, breast ultrasounds, a clinical examination and a biological assessment will be performed. In addition, it will be proposed to patients to continue treatment during 2 additional years. At the end of the third year,the same examinations will be performed.

Interventions

Sponsors

Laboratoires Arkopharma
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
45 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Not hysterectomised women * Post menopausal (at least 2 years) * FSH superior to 30 UI/l and oestradiol inferior to 35 ng/ml * Presenting with hot flushes (but not incapacitating) or climacteric symptoms

Exclusion criteria

* History of endometrial hyperplasia * Known hormono-dependent malignant tumours * BMI superior to 30 Kg/m2 * Uncontrolled arterial hypertension * Known renal or liver insufficiency * Recent or evolutive thromboembolic disease * Unexplained bleeding, endometrial polyps, submucous myomas, active endometriosis, ovarian cyst superior to 30 mm * Local hormonal treatment, raloxifene,tibolone within the 3 months before V1 and during the study * HRT and DHEA within the 3 months before V2 and during the study * isoflavones within the 2 months before V2 and during the study * clonidine, beta-alanine, veralipride within 1 month before V1 and during the study.

Design outcomes

Primary

MeasureTime frame
- Endometrial innocuity (endometrial biopsy result)

Secondary

MeasureTime frame
- Mammary innocuity (mammography results)
- climacteric symptoms
-Lipid profile
-gynaecological and general safety

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026